On September 25, 2018 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, reported that company management will participate in three upcoming conferences (Press release, Xencor, SEP 25, 2018, View Source [SID1234529623]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2018 Cantor Global Healthcare Conference
Date: Tuesday, October 2, 2018
Location: New York, NY
Presentation Time: 10:55 a.m. ET

Leerink Partners Roundtable Series: Rare Disease & Oncology
Date: Wednesday, October 3, 2018
Location: New York, NY
Presentation Time: 10:00 a.m. ET

BTIG Biotech Conference
Date: Thursday, October 25, 2018
Location: New York, NY
Management will be available for one-on-one meetings.
Live webcasts of both the 2018 Cantor Global Healthcare Conference and the Leerink Partners Roundtable Series: Rare Disease & Oncology presentations will be available under "Events & Presentations" in the Investors section of the Company’s website located at View Source A replay of the presentations will be posted on the Xencor website approximately one hour after the live events and will be available for 90 days following the presentations.

On September 25, 2018 Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, reported the company will present at the Ladenburg Thalmann 2018 Healthcare Conference on October 2, 2018 at 12:00 pm Eastern Time in New York, NY (Press release, Alpine Immune Sciences, SEP 25, 2018, View Source [SID1234529574]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available online in the investor relations section of the company’s website at View Source A replay of the presentation will be available on the company website for 90 days following the webcast.

On September 25, 2018, Aduro Biotech, Inc. ("we" or the "Company")reported it received written notices of termination from Janssen Biotech, Inc. ("Janssen") for its Research and License Agreements pertaining to the Company’s proprietary attenuated strains of Listeria for treatment of lung and prostate cancers (Filing, 8-K, Aduro Biotech, SEPT 25, 2018, View Source [SID1234529939]). Specifically, Janssen delivered notice for the following agreements (the "Janssen Agreements"): (i) the Research and License Agreement, dated as of October 13, 2014, as amended by that certain Amendment to Research and License Agreements, dated as of November 11, 2015 (the "Amendment"); (ii) the Research and License Agreement, dated as of May 27, 2014, as amended by the Amendment; and (iii) the GVAX Prostate License Agreement, dated as of May 27, 2014. The terminations are effective December 24, 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the Janssen Agreements, the Company granted Janssen an exclusive, worldwide license to research, develop, manufacture, use, sell and otherwise exploit products containing ADU-214, ADU-741 and GVAX Prostate for any and all uses. Additionally, the Company granted Janssen exclusive rights to develop products utilizing the Company’s proprietary attenuated strains of Listeria for treatment of lung and prostate cancers. The Company previously received upfront license fees and milestone payments upon completion of various development activities and was eligible to receive future contingent payments based on development, regulatory and commercial milestones as well as royalties on any net sales of licensed products by Janssen under each of the Janssen Agreements. Pursuant to the terms of the Janssen Agreements, upon Janssen’s termination, the Company regains worldwide rights for the development and commercialization of products containing ADU-214, ADU-741 and GVAX Prostate for any and all uses. In addition, Janssen will have certain obligations as set forth in the Janssen Agreements, including (i) immediately ceasing its use of any Company intellectual property and (ii) promptly returning or destroying any materials related to the development or manufacturing of the products containing ADU-214, ADU-741 and GVAX Prostate.

The foregoing descriptions of the Janssen Agreements do not purport to be complete and are qualified in their entirety by the full text of the agreements. The Janssen Agreements were filed as Exhibits 10.18, 10.19 and 10.20 to the Company’s Registration Statement on Form S-1, filed with the Securities and Exchange Commission on March 11, 2015, and the Amendment was filed as Exhibit 10.41 to the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 8, 2016.

On September 25, 2018 Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, reported that management will participate at both the upcoming KBC Healthcare Conference and the Leerink Partners Roundtable Series: Rare Disease & Oncology (Press release, Celyad, SEP 25, 2018, View Source [SID1234532510]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The KBC Healthcare Conference will take place in New York, NY on September 27, 2018.

The Leerink Partners Roundtable Series: Rare Disease & Oncology will take place in New York, NY on October 2-3, 2018 and the Company is scheduled to present on Wednesday, October 3 at 4:00 p.m. ET. A live webcast of the presentation can be accessed at View Source An archived webcast recording will also be available under Events & Webcasts in the Investors section of the Company’s website.

On September 25, 2018 Array BioPharma Inc. (Nasdaq: ARRY) reported that its Chief Executive Officer, Ron Squarer, will speak at the 2018 Cantor Global Healthcare Conference in New York (Press release, Array BioPharma, SEP 25, 2018, View Source [SID1234529559]). The public is welcome to participate in the conference through a webcast on the Array BioPharma website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event:

Cantor Global Healthcare Conference

Presenter:

Ron Squarer, Chief Executive Officer, Array BioPharma

Date:

Tuesday, October 2, 2018

Time:

9:45 a.m. Eastern Time

Webcast:

View Source